van Westerloo DJ, Rauws EA, Hommes D, de Vos AF, van der Poll T, Powers BL, et al. (August 2008). "Pre-ERCP infusion of semapimod, a mitogen-activated protein kinases inhibitor, lowers post-ERCP hyperamylasemia but not pancreatitis incidence". Gastrointestinal Endoscopy. 68 (2): 246–54. doi:10.1016/j.gie.2008.01.034. PMID18455169.
Ulrich P, Cerami A (January 1984). "Trypanocidal 1,3-arylene diketone bis(guanylhydrazone)s. Structure-activity relationships among substituted and heterocyclic analogues". Journal of Medicinal Chemistry. 27 (1): 35–40. doi:10.1021/jm00367a007. PMID6690682.
Atkins MB, Redman B, Mier J, Gollob J, Weber J, Sosman J, et al. (March 2001). "A phase I study of CNI-1493, an inhibitor of cytokine release, in combination with high-dose interleukin-2 in patients with renal cancer and melanoma". Clinical Cancer Research. 7 (3): 486–92. PMID11297238.
van Westerloo DJ, Rauws EA, Hommes D, de Vos AF, van der Poll T, Powers BL, et al. (August 2008). "Pre-ERCP infusion of semapimod, a mitogen-activated protein kinases inhibitor, lowers post-ERCP hyperamylasemia but not pancreatitis incidence". Gastrointestinal Endoscopy. 68 (2): 246–54. doi:10.1016/j.gie.2008.01.034. PMID18455169.
Ulrich P, Cerami A (January 1984). "Trypanocidal 1,3-arylene diketone bis(guanylhydrazone)s. Structure-activity relationships among substituted and heterocyclic analogues". Journal of Medicinal Chemistry. 27 (1): 35–40. doi:10.1021/jm00367a007. PMID6690682.